Foghorn Therapeutics (FHTX) PT Raised to $28 at Goldman Sachs, Following Clinical Update

March 19, 2021 12:53 PM EDT
Get Alerts FHTX Hot Sheet
Price: $11.50 -2.38%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Goldman Sachs analyst Paul Choi raised the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $28.00 (from $27.00) while maintaining a Buy rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities

Goldman Sachs